---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-235275"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:22:28.354000+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics prices upsized $500M public offering at $50/share; net proceeds ~$472M

## Summary
- Pricing of 10,000,000 shares of common stock at $50.00/share for gross proceeds of $500.0 million.
- Net proceeds estimated at approximately $472.0 million (or ~$542.9 million if 1.5M share option exercised).
- Underwriters granted 30-day option to purchase up to 1,500,000 additional shares; closing expected October 10, 2024.
- Proceeds to fund R&D of clinical-stage candidates, pre-commercialization activities, and general corporate purposes.
- Leerink Partners and Morgan Stanley acting as joint bookrunning managers for the offering.

## SEC filing metadata
- accession: 0001193125-24-235275
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524235275/0001193125-24-235275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524235275/d857933d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-235275
- JSON: https://secwatch.observer/filing/0001193125-24-235275.json
- Plain text: https://secwatch.observer/filing/0001193125-24-235275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.